- Home
- REFR vs BTAI Comparison
REFR vs BTAI Comparison
Compare REFR & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFR | BTAI |
|---|---|---|
| Founded | 1965 | 2017 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2M | 35.6M |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | REFR | BTAI |
|---|---|---|
| Price | $0.87 | $1.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 26.9K | ★ 928.7K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.63 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,488,642.00 | N/A |
| Revenue This Year | N/A | $197.82 |
| Revenue Next Year | N/A | $910.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $1.01 |
| 52 Week High | $2.70 | $8.08 |
Technical Indicators
Market Signals| Indicator | REFR | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 39.90 | 55.97 |
| Support Level | $0.82 | N/A |
| Resistance Level | $1.03 | $1.77 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 23.63 | 88.14 |
Price Performance
Historical ComparisonAbout REFR Research Frontiers Incorporated
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.